I-Mab Biopharma
IMAB
#8993
Rank
A$0.12 B
Marketcap
$1.48
Share price
-2.14%
Change (1 day)
-36.27%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): A$47.32 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is A$55.99 Million. In 2022 the company made a revenue of -A$49.47 Million a decrease over the revenue in the year 2021 that were of A$21.27 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) A$47.32 M
2022-A$49.47 Million-332.55%
2021A$21.27 M-94.16%
2020 A$0.36 B5407.66%
2019 A$6.61 M-45.08%
2018 A$12.04 M340.25%
2017A$2.73 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
A$0.34 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.10 B 1,870.10%๐Ÿ‡บ๐Ÿ‡ธ USA